Boston, US: Phesi, a global provider of patient-centric data analytics, has launched Version 2 of its award-winning Trial Accelerator™ platform, with enhanced AI capabilities and new features for clinical trial sponsors. Over the last 18 months, Phesi has focused on upgrading the platform, refining proprietary algorithms and expanding the data science team with new hires. Following the updates, Trial Accelerator™ has reached a new milestone and now contains data from over 132 million patients in rare and commonly studied diseases – maintaining its position as the world’s largest and most dynamic clinical development database. This unparalleled volume of data allows sponsors to access patient data in more than 400,000 cohorts, simulate clinical development design and operations with greater accuracy, and increase trial success.
“Phesi has been working with the clinical development industry for two decades, and over that time we have seen significant advances – from digital twin technology to precision medicine,” commented Dr Gen Li, President and CEO, Phesi. “In the last 18 months, we have refined the Trial Accelerator™ platform further to improve sponsors’ approaches to patient selection through optimized program and protocol design plus country and investigator site analysis. Our guiding principle is that the patient must be at the heart of development – everything starts with the patient and gaining a deep understanding of them. With patient-centered data science, sponsors can optimize trial design, reduce patient burden, and select investigator sites and countries with far greater precision. This is essential to increase the speed of clinical development while controlling costs, helping get much-needed treatments to patients faster. A data-driven approach enables sponsors to withstand the increasing complexity of clinical development and be prepared for future challenges.”
The second version of Trial Accelerator™ includes:
- An extended catalogue of Digital Patient Profiles (DPP) containing granular patient data across 42 indications at cohort and patient level. Each DPP delivers a statistical view of patient attributes to improve protocol design and accelerate the adoption of external control arms.
- The new Patient Access Score based on DPP provides a unique performance measure of an investigator site’s potential to access the target patient population and to eliminate activation of non-enrolling investigator sites, reducing protocol amendments and costs.
- Patient Burden Score predicts the frequency a patient will visit an investigator site, what procedures will be conducted, and what data will be recorded during each visit. The metric improves investigator site performance, accelerates enrolment, and reduces patient burden.
- The self-service Investigator Site Profile Solution provides a detailed profile of investigator sites’ expertise, workload and clinical relevance, and prediction of their future enrollment performance, allowing users to select the best locations for the design of their study with precision and to minimize non-enrolling investigator sites.
- Health Check and Trial Rescue Service allows sponsors to submit protocols and investigator site nominations for review. Phesi then offers rapid real-time insights on key design elements, such as inclusion and exclusion criteria, to inform the trial planning process.
- Patient Enrolment Rate enables predictive scenario modelling of different protocol design criteria based on four key elements: indication (including different biomarkers and treatment modalities), phase of trial, country, and investigator site. This is done using a proprietary GSER (Gross Site Enrollment Rate) modeling platform.
- Patient Diversity Score ensures representation of patient subpopulations based on factors such as race, sex, and treatment settings – guaranteeing that medical and scientific conclusions benefit all patients.
“In today’s challenging economic climate, return-on-investment (ROI) is a pressing issue for the pharma industry,” explained Jonathan Peachey, COO and Board Director, Phesi. “Clients are under immense pressure to boost ROI on every project while achieving more with fewer resources. Trial Accelerator empowers sponsors to make data-driven decisions in the trial planning and execution processes, using Digital Patient Profiles and digital twins to demonstrate efficacy and safety in relevant patient cohorts. These latest updates underline Phesi’s commitment to innovating and helping our clients manage diverse portfolios – allowing them to deliver smarter trials for faster cures.”
The traditional data management function of collecting and interpreting patient data from clinical trials is transforming. Digitalized patient data can optimize development plans, trial protocols and design, improve real-time decision-making, and enhance or even replace data collected from trials – reducing the burden on both patients and investigator sites. These latest updates to Trial Accelerator™ represent an accumulation of 20 years’ worth of effort collating data from product and disease registries, electronic health records, medical claims data, and almost 100,000 dynamically updated sources.
Phesi is attending the annual SCOPE summit from February 3-6, at Booth 923. Please visit https://info.phesi.com/scope-2025 to book a conversation with the Phesi team.
